Pooled analysis reveals persistently poor survival in metastatic rhabdomyosarcoma with adverse prognostic factors, highlighting the urgent need for novel therapeutic approaches.
Outcome remains poor for patients with metastatic RMS and multiple ORFs. Because of the design of the studies, it was not possible to determine whether the intensive induction regimen and/or the addition of maintenance treatment resulted in apparent improvement of outcome compared with historical cohorts. Further studies, with novel treatment approaches are urgently needed, to improve outcome for the group of patients with adverse prognostic factors.
No takes yet. Share an insight, caveat, or question.
Schoot et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: